Abcuro
Clinical-stage immunotherapies targeting pathogenic cytotoxic T cells in autoimmune disease.
$66MSeries D
Role not disclosedBC
Bain Capital Life Sciences
Activity from announced rounds
Activity in this selectiona16z-bio-health-1883279d
- Rounds participated in
- 4
- Confirmed lead rounds
- — 4 roles undisclosed
- New companies
- 4 First participation on record · 0 follow-on
- Funding in participating rounds
- $566M 4 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
4 in this selectionAdvanCell
AdvanCell develops targeted alpha radiopharmaceuticals for cancer using Lead-212, with integrated isotope supply and manufacturing.
$315MSeries D
Role not disclosedCereVasc
Develops minimally invasive eShunt System to treat communicating hydrocephalus and other neurological diseases
$85MSeries C
Role not disclosedImperative Care
Develops treatments for patients suffering from thromboembolic disease
$100MGrowth
Role not disclosed